Troglitazone hepatotoxicity: are we getting closer to understanding idiosyncratic liver injury?
Jaeschke
Hartmut
H
Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, MS 1018, Kansas City, Kansas 66160, USA. hjaeschke@kumc.edu
D000818:Animals; D056486:Chemical and Drug Induced Liver Injury; D002839:Chromans / Q000633:toxicity*; D004195:Disease Models, Animal; D006801:Humans; D007004:Hypoglycemic Agents / Q000633:toxicity*; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D008107:Liver Diseases / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D051379:Mice; D008822:Mice, Transgenic; D008930:Mitochondria, Liver / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D028361:Mitochondrial Diseases / Q000235:genetics / Q000378:metabolism* / Q000473:pathology; D018384:Oxidative Stress / Q000187:drug effects*; D017382:Reactive Oxygen Species / Q000378:metabolism; D013482:Superoxide Dismutase / Q000172:deficiency / Q000235:genetics / Q000378:metabolism; D045162:Thiazolidinediones / Q000633:toxicity*; D000077288:Troglitazone; D000099156:Superoxide Dismutase 2
D002839:Chromans; D007004:Hypoglycemic Agents; D017382:Reactive Oxygen Species; D013482:Superoxide Dismutase; D045162:Thiazolidinediones; D000077288:Troglitazone; D000099156:Superoxide Dismutase 2